Jakob Lovén
Jakob Lovén
Whitehead Institute for Biomedical Research
Verified email at wi.mit.edu - Homepage
Title
Cited by
Cited by
Year
Selective inhibition of tumor oncogenes by disruption of super-enhancers
J Lovén, HA Hoke, CY Lin, A Lau, DA Orlando, CR Vakoc, JE Bradner, ...
Cell 153 (2), 320-334, 2013
15092013
Transcriptional amplification in tumor cells with elevated c-Myc
CY Lin, J Lovén, PB Rahl, RM Paranal, CB Burge, JE Bradner, TI Lee, ...
Cell 151 (1), 56-67, 2012
10702012
Master transcription factors determine cell-type-specific responses to TGF-β signaling
AC Mullen, DA Orlando, JJ Newman, J Lovén, RM Kumar, S Bilodeau, ...
Cell 147 (3), 565-576, 2011
5072011
Revisiting global gene expression analysis
J Lovén, DA Orlando, AA Sigova, CY Lin, PB Rahl, CB Burge, DL Levens, ...
Cell 151 (3), 476-482, 2012
4582012
Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons
Y Li, H Wang, J Muffat, AW Cheng, DA Orlando, J Lovén, S Kwok, ...
Cell stem cell 13 (4), 446-458, 2013
2212013
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1
M Lerner, M Harada, J Lovén, J Castro, Z Davis, D Oscier, M Henriksson, ...
Experimental cell research 315 (17), 2941-2952, 2009
1492009
MYCN-regulated microRNAs repress estrogen receptor-α (ESR1) expression and neuronal differentiation in human neuroblastoma
J Lovén, N Zinin, T Wahlström, I Müller, P Brodin, E Fredlund, U Ribacke, ...
Proceedings of the National Academy of Sciences 107 (4), 1553-1558, 2010
1362010
Genome-wide localization of small molecules
L Anders, MG Guenther, J Qi, ZP Fan, JJ Marineau, PB Rahl, J Loven, ...
Nature biotechnology 32 (1), 92, 2014
1282014
MicroRNA-203 functions as a tumor suppressor in basal cell carcinoma
E Sonkoly, J Loven, N Xu, F Meisgen, T Wei, P Brodin, V Jaks, M Kasper, ...
Oncogenesis 1 (3), e3-e3, 2012
792012
Targeting MYC-regulated miRNAs to combat cancer
A Frenzel, J Lovén, MA Henriksson
Genes & cancer 1 (6), 660-667, 2010
562010
c‐Myc‐dependent etoposide‐induced apoptosis involves activation of Bax and caspases, and PKCdelta signaling
A Albihn, J Lovén, J Ohlsson, LM Osorio, M Henriksson
Journal of cellular biochemistry 98 (6), 1597-1614, 2006
432006
Superenhancer analysis defines novel epigenomic subtypes of non-APL AML, including an RARα dependency targetable by SY-1425, a potent and selective RARα agonist
MR McKeown, MR Corces, ML Eaton, C Fiore, E Lee, JT Lopez, ...
Cancer discovery 7 (10), 1136-1153, 2017
402017
MicroRNA-203 inversely correlates with differentiation grade, targets c-MYC, and functions as a tumor suppressor in cSCC
W Lohcharoenkal, M Harada, J Lovén, F Meisgen, NX Landén, L Zhang, ...
Journal of Investigative Dermatology 136 (12), 2485-2494, 2016
232016
Regulation of nuclear hormone receptors by MYCN-driven miRNAs impacts neural differentiation and survival in neuroblastoma patients
D Ribeiro, MDR Klarqvist, UK Westermark, G Oliynyk, J Dzieran, A Kock, ...
Cell reports 16 (4), 979-993, 2016
172016
Genome-wide determination of drug localization
L Anders, MG Guenther, J Qi, ZP Fan, JJ Marineau, PB Rahl, J Lovén, ...
Nature biotechnology 32 (1), 92, 2014
102014
Super-enhancers and methods of use thereof
RA Young, W Whyte, D Hnisz, J Loven, H Hoke, D Orlando, CY Lin, T Lee
US Patent 9,181,580, 2015
22015
Discovery and characterization of super-enhancer-associated dependencies in acute myeloid leukemia
MR Corces-Zimmerman, M Eaton, J Lopez, N Ke, C Fritz, E Olson, ...
Blood, The Journal of the American Society of Hematology 124 (21), 3539-3539, 2014
22014
Super-enhancers and methods of use thereof
RA Young, W Whyte, D Hnisz, J Loven, H Hoke, D Orlando, CY Lin, T Lee
US Patent App. 14/063,337, 2014
22014
MiR-203 functions as a tumor suppressor microRNA in basal cell carcinoma
E Sonkoly, J Loven, T Wei, N Xu, F Meisgen, P Brodin, V Jaks, M Kasper, ...
JOURNAL OF INVESTIGATIVE DERMATOLOGY 131, S20-S20, 2011
12011
Superenhancer Analysis Defines Novel Epigenomic Subtypes of Non-APL AML, Including an RARDependency Targetable by SY-1425, a Potent and Selective RARAgonist
MR McKeown, MR Corces, ML Eaton, C Fiore, E Lee, JT Lopez, ...
2017
The system can't perform the operation now. Try again later.
Articles 1–20